Document Detail

Biochemical and behavioral characterization of novel methylphenidate analogs.
MedLine Citation:
PMID:  11961053     Owner:  NLM     Status:  MEDLINE    
As part of a project to develop treatment agents for cocaine abuse, (+/-)-threo-methylphenidate (TMP) and 11 analogs were characterized biochemically and behaviorally to assess their potential as anti-cocaine medications. The compounds contained aryl and/or nitrogen substitutions, and/or replacement of the ester function by an alcohol or ether. All of the analogs, except for the N-methyl-substituted compounds, showed increased inhibitory potency against (3)H-(-)-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane 1,5-naphthalenedisulfonate ([(3)H]WIN 35,428) ([(3)H]WIN) binding to the dopamine transporter, compared with TMP. In general, parallel results were obtained for inhibition of [(3)H]dopamine ([(3)H]DA) uptake. Although compounds with N-substitutions were proportionally less potent at blocking DA uptake than WIN binding (compared with the unsubstituted compounds), one such compound that was 6-fold more potent against [(3)H]WIN binding than [(3)H]DA uptake did not attenuate inhibition by cocaine of synaptosomal [(3)H]DA transport. The compounds were significantly less potent in displacing [(3)H]citalopram binding from the serotonin transporter. In cocaine discrimination studies in rats, all but two of the analogs (both N-substituted) completely generalized with the cocaine stimulus. Robust positive correlations were observed between potency in the drug discrimination assay and activity at the dopamine transporter, but not the serotonin transporter. When tested for their ability to alter cocaine discrimination, four of the analogs (three of which had N-substitutions and shallow dose-response curves as cocaine substitutes) actually enhanced cocaine discrimination, often at combined doses of cocaine and test compound that were inactive when given separately. Taken together, the results suggest that TMP analogs may have potential as substitution therapies for the treatment of cocaine abuse.
M M Schweri; H M Deutsch; A T Massey; S G Holtzman
Related Documents :
23403063 - Laccase from pycnoporus cinnabarinus and phenolic compounds: can the efficiency of an e...
23827363 - Comparative study of the photodegradation of bisphenol a by ho, so4(-) and co3(-)/hco3 ...
25358013 - Catalytic wet oxidation of aqueous methylamine: comparative study on the catalytic perf...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  301     ISSN:  0022-3565     ISO Abbreviation:  J. Pharmacol. Exp. Ther.     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-04-18     Completed Date:  2002-05-13     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  527-35     Citation Subset:  IM    
Division of Basic Medical Sciences, Mercer University School of Medicine, Macon, Georgia 31207, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Discrimination Learning / drug effects*
Dose-Response Relationship, Drug
Models, Animal
Rats, Sprague-Dawley
Thymidine Monophosphate / analogs & derivatives,  pharmacology*
Grant Support
Reg. No./Substance:
365-07-1/Thymidine Monophosphate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol...
Next Document:  Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK...